Clinical Trials Browser

Phase 1/2 × Withdrawn × ibrutinib × Clear all

NCT04607772 2025-10-03

Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL)

Phase 1/2 Withdrawn

Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT02677948 2017-09-06

Multicenter Study of Pacritinib Combined With Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

Phase 1/2 Withdrawn

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell